Literature DB >> 21102532

Pancreatic cancer: understanding and overcoming chemoresistance.

Zhiwei Wang1, Yiwei Li, Aamir Ahmad, Sanjeev Banerjee, Asfar S Azmi, Dejuan Kong, Fazlul H Sarkar.   

Abstract

Pancreatic cancer is a highly aggressive malignancy. This feature is believed to be partly attributable to the chemotherapy-resistant characteristics of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells. Accumulating evidence suggests that several new and emerging concepts might be important in the drug-resistant phenotype of these cell types. An understanding of the molecular mechanisms underlying drug resistance in patients with pancreatic cancer might help researchers to devise novel strategies to overcome such resistance. In particular, microRNAs (miRNAs) seem to be critical regulators of drug resistance in pancreatic cancer cells. Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102532     DOI: 10.1038/nrgastro.2010.188

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  59 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

3.  Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

Authors:  Shadan Ali; Aamir Ahmad; Sanjeev Banerjee; Subhash Padhye; Kristin Dominiak; Jacqueline M Schaffert; Zhiwei Wang; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 4.  Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-06-22

5.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

Authors:  Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

9.  Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.

Authors:  Jong-Kook Park; Eun Joo Lee; Christine Esau; Thomas D Schmittgen
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

10.  A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics.

Authors:  Y H Wang; F Li; B Luo; X H Wang; H C Sun; S Liu; Y Q Cui; X X Xu
Journal:  Neoplasma       Date:  2009       Impact factor: 2.575

View more
  158 in total

1.  Pancreatic Cancer: a Challenge to Cure.

Authors:  M Tewari
Journal:  Indian J Surg       Date:  2015-10-19       Impact factor: 0.656

2.  Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells.

Authors:  Zhi-Gang Chang; Jun-Min Wei; Chang-Fu Qin; Kun Hao; Xiao-Dong Tian; Kun Xie; Xue-Hai Xie; Yin-Mo Yang
Journal:  Dig Dis Sci       Date:  2012-01-21       Impact factor: 3.199

3.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

Review 4.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

Review 5.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

6.  Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.

Authors:  Sun Mi Lee; Matthew H G Katz; Li Liu; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

7.  Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Bhavitavya Nijampatnam; Sadanandan E Velu; Ke-He Ruan; Ming Hu; Jianwei Zhou; Ruiwen Zhang
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

Review 8.  The emerging molecular machinery and therapeutic targets of metastasis.

Authors:  Yutong Sun; Li Ma
Journal:  Trends Pharmacol Sci       Date:  2015-05-01       Impact factor: 14.819

9.  Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Authors:  Sabiha Kazim; Mokenge P Malafa; Domenico Coppola; Kazim Husain; Sherma Zibadi; Trinayan Kashyap; Marsha Crochiere; Yosef Landesman; Tami Rashal; Daniel M Sullivan; Amit Mahipal
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

10.  The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.

Authors:  Ning An; Donghui Cheng
Journal:  Pathol Oncol Res       Date:  2018-11-07       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.